Phyo T. Htoo

Dec 11, 2024 | jamanetwork.com | Helen Tesfaye |Julie M. Paik |Miin Roh |Phyo T. Htoo

Empagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes Key PointsQuestion  Is there an association between empagliflozin and the risk of nonproliferative diabetic retinopathy (NPDR) and diabetic retinopathy (DR) progression in patients with type 2 diabetes (T2D)?

Sep 27, 2024 | radcliffecvrm.com | Helen M. Colhoun |John McMurray |Richard E. Pratley |Phyo T. Htoo

EASD 24 - We are joined by Dr Helen Coulhoun (University of Edinburgh, UK) to discuss the key findings of a prespecified analysis of the SELECT trial, which investigated the effectiveness of semaglutide in reducing major cardiac events in the presence of impaired kidney function in patients with overweight and obesity.

Sep 11, 2024 | radcliffecardiology.com | Richard E. Pratley |Phyo T. Htoo |Julia Grapsa |Marta Sitges

Skip to main content Video Published: Views: 14 Likes: 0 Average (ratings) EASD 24 - Dr Phyo Htoo (Harvard Medical School, Boston, MA, US) joins us to discuss a study investigating the comparative effectiveness of empagliflozin and glucagon-like peptide-1 receptor agonists in combination as compared to either medication alone in patients with type 2 diabetes. Interview Questions:1. What was the reasoning for this study? 2.

Oct 25, 2023 | onlinelibrary.wiley.com | Phyo T. Htoo |Robert J Glynn |Shirley Wang |Julie M. Paik

CONFLICT OF INTEREST STATEMENT Dr. Htoo was previously an employee of Johnson & Johnson on work unrelated to the submitted work. Dr. Schneeweiss reported receiving grants from Boehringer Ingelheim and personal fees from Aetion outside the submitted work. Dr. Glynn reported receiving grants from Amarin Corporation, Kowa Pharmaceuticals America, Novartis, and Pfizer outside the submitted work.